← Evidence map

ArticleGenes2022

PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma.

Yinkui Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma. | OpenQuestion